Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization (IS) (2016 - 2026)

Sunshine Biopharma filings provide 7 years of Depreciation & Amortization (IS) readings, the most recent being $42618.0 for Q1 2024.

  • On a quarterly basis, Depreciation & Amortization (IS) rose 22.78% to $42618.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $83911.0, a 87.69% increase, with the full-year FY2025 number at $332070.0, up 48.56% from a year prior.
  • Depreciation & Amortization (IS) hit $42618.0 in Q1 2024 for Sunshine Biopharma, up from $34710.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $42618.0 in Q1 2024 to a low of $3110.0 in Q1 2022.
  • Median Depreciation & Amortization (IS) over the past 3 years was $34710.0 (2023), compared with a mean of $26812.7.
  • Biggest five-year swings in Depreciation & Amortization (IS): skyrocketed 1016.08% in 2023 and later grew 22.78% in 2024.
  • Sunshine Biopharma's Depreciation & Amortization (IS) stood at $3110.0 in 2022, then skyrocketed by 1016.08% to $34710.0 in 2023, then increased by 22.78% to $42618.0 in 2024.
  • The last three reported values for Depreciation & Amortization (IS) were $42618.0 (Q1 2024), $34710.0 (Q1 2023), and $3110.0 (Q1 2022) per Business Quant data.